TrialCell reports. Medicine2026

Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial.

Ming Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.